Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Medpace Holdings Inc (MEDP) Price & Performance

Allbirds IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Medpace Holdings Inc — how do they compare? Allbirds Inc trades at $3.01 (market cap $25.89M), while Medpace Holdings Inc trades at $532.54 (market cap $15.31B). The key difference: Medpace Holdings Inc is far larger — about 591.3× Allbirds Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.

BIRDMEDP
Market Cap
$25.89M$15.31B
Sector
Consumer CyclicalTechnology
52-Week High
$16.99$620.59
52-Week Low
$2.39$308.88
Enterprise Value
$44.76M$14.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $3.00, down 4.15% today, amid a complete business pivot from footwear to AI infrastructure. The stock shows a bearish technical trend with all moving averages signaling sell, while oscillators suggest potential oversold conditions. Fundamentally, the company reports declining revenue ($152M in 2025) and persistent losses (-$77M net income), though it maintains a low P/S ratio of 0.17. Recent news highlights the strategic shift, including a rebrand to Smartbird and appointment of a new CEO from Amazon Web Services (Reuters, June 17, 2026).

The outlook is highly speculative, driven by the unproven AI strategy rather than current fundamentals. Investment opportunity lies in potential AI sector growth, but risks include execution challenges, cash burn (-$40M net cash flow in 2025), and intense competition. Analysts are cautious with 79% hold ratings, reflecting uncertainty about the pivot's success. Shareholders face volatility as the company transitions from a tangible product business to technology infrastructure.

Medpace Holdings Inc

MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.

Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP